Ex Parte Shear - Page 4


                     Appeal No. 2006-0819                                                                        Page 4                         
                     Application No. 09/929,862                                                                                                 

                             [T]he difference between the subject matter sought to be patented                                                  
                             and the prior art are such that the subject matter as a whole would                                                
                             have been obvious at the time the invention was made to a person                                                   
                             having ordinary skill in the art to which said subject matter pertains                                             
                             because Roth teaches the presently claimed salt forms and                                                          
                             hydroxyl acid forms of atorvastatin . . . as being effective [sic] HMG-                                            
                             CoA reductase inhibitors and the skilled artisan would have been                                                   
                             motivated to alternatively use these compounds of Roth for the                                                     
                             purpose taught by Dennino [ ] for atorvastatin because not only was                                                
                             it known that atorvastatin (see Dennino [ ] as referenced above)                                                   
                             and the presently claimed salt forms and hydroxy acid forms of                                                     
                             atorvastatin were known to function as HMG-CoA-reductase                                                           
                             inhibitors (see Roth as referenced above), but Dennino  [ ] teach                                                  
                             that HMG-CoA reductase inhibitors in general could be combined                                                     
                             with [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-                                                 
                             amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-                                                       
                             carboxylic acid ethyl ester for the purposes taught therein and                                                    
                             presently claimed.                                                                                                 

                     Id. at 3                                                                                                                   
                             “In rejecting claims under 35 U.S.C. § 103, the examiner bears the initial                                         
                     burden of presenting a prima facie case of obviousness.  Only if that burden is                                            
                     met, does the burden of coming forward with evidence or argument shift to the                                              
                     applicant.”  In re Rijckaert, 9 F.3d 1531, 1532, 28 USPQ2d 1955, 1956 (Fed. Cir.                                           
                     1993) (citations omitted).  The test of obviousness is “whether the teachings of                                           
                     the prior art, taken as a whole, would have made obvious the claimed invention.”                                           
                     In re Gorman, 933 F.2d 982, 986, 18 USPQ2d 1885, 1888 (Fed. Cir. 1991).  We                                                
                     conclude that the examiner has met the burden of establishing a prima facie case                                           
                     of obviousness, and the rejection is affirmed.                                                                             
                             Appellant argues that the examiner has failed to make out a prima facie                                            
                     case of obviousness.  See Appeal Brief, page 6.  Appellant asserts, relying on In                                          
                     re Geiger, 815 F.2d 686, 688 2 USPQ2d 1276, 1278 (Fed. Cir. 1987), “[w]hile                                                





Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next 

Last modified: November 3, 2007